Correlation Analysis of FⅧGene Mutation and the Production of FⅧ Inhibitor with Severe Hemophilia A Patients in a Single Medical Center.
10.19746/j.cnki.issn.1009-2137.2022.05.036
- Author:
Lyu-Kai ZHU
1
;
Xia-Lin ZHANG
1
;
Xiu-E LIU
1
;
Xiu-Yu QIN
1
;
Gang WANG
2
;
Lin-Hua YANG
3
Author Information
1. Institute of Hematology, Department of Hematology, The Second Hospital of Shanxi Medical University(The Second Clinical Medical College), Taiyuan 030001, Shanxi Province, China.
2. Institute of Hematology, Department of Hematology, The Second Hospital of Shanxi Medical University(The Second Clinical Medical College), Taiyuan 030001, Shanxi Province, China,E-mail：g.wang@sxmu.edu.cn.
3. Institute of Hematology, Department of Hematology, The Second Hospital of Shanxi Medical University(The Second Clinical Medical College), Taiyuan 030001, Shanxi Province, China,E-mail：yanglh5282@163.com.
- Publication Type:Journal Article
- Keywords:
FⅧ gene mutation;
FⅧ inhibitor;
factor Ⅷ;
hemophilia A
- MeSH:
Codon, Nonsense;
DNA Mutational Analysis;
Factor VIII/genetics*;
Hemophilia A/genetics*;
Humans;
Introns;
Mutation
- From:
Journal of Experimental Hematology
2022;30(5):1536-1540
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between the type of FⅧgene mutation and the development of FⅧ inhibitors in patients with severe haemophilia A (HA).
METHODS:The medical records of 172 patients with severe hemophilia A from January 2009 to September 2020 were reviewed. The types of FⅧgene mutations and the production of factor Ⅷ inhibitors were collected and divided into high-risk mutation group ( intron 1 inversions, large deletions, nonsense mutations), low-risk mutation group (missense mutations, small deletions and insertions, splice site mutations) and intron 22 inversions group. The correlation of FⅧgenotype and the production of FⅧ inhibitors in patients with HA were analyzed.
RESULTS:Among 172 patients with severe HA, 21 cases(12.21%) developed FⅧ inhibitors. The cumulative incidence of FⅧ inhibitor development was 32%(10/31) in high risk group (75% patients with large deletions, 43% patients with intron 1 inversions, 20% patients with nonsense mutations) and 5%(2/43) in low risk group(6% patients with missense mutations, 5% patients with small deletions or insertions and 0% patient with a splice site mutation) and 9%(9/98) in intron 22 inversions group. Compared with the risk of FⅧ inhibitor development in intron 22 inversions group, the risk of FⅧ inhibitor development in high risk group was higher (OR＝4.7, 95% CI： 1.7-13.0), the risk of FⅧ inhibitor development in low risk group was equal (OR＝0.5, 95% CI： 0.1-2.3). Compared with the risk of inhibitor development in low risk group, the risk of FⅧ inhibitor development in high risk group was higher (OR＝9.8, 95% CI： 2.0-48.7).
CONCLUSION:Gene mutations of patients with severe HA in high-risk group which include intron 1 inversions, large deletions, nonsense mutations are a risk factor for FⅧ inhibitor production.
